Kura Oncology (NASDAQ:KURA) Insider Brian Powl Sells 15,430 Shares of Stock

Posted by Stanley Muller on Sep 29th, 2026

Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) insider Brian Powl sold 15,430 shares of the business’s stock in a transaction that occurred on Tuesday, September 29th. The stock was sold at an average price of $10.75, for a total value of $165,872.50. Following the sale, the insider owned 136,819 shares of the company’s stock, valued at approximately $1,470,804.25. This represents a 10.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kura Oncology Stock Performance

Shares of Kura Oncology stock traded up $0.20 on Tuesday, hitting $10.81. The stock had a trading volume of 1,890,260 shares, compared to its average volume of 1,673,937. The stock has a market cap of $961.66 million, a price-to-earnings ratio of -3.21 and a beta of 0.44. The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12. Kura Oncology, Inc. has a twelve month low of $7.36 and a twelve month high of $13.90. The business’s 50 day moving average is $11.22 and its two-hundred day moving average is $10.15.

Kura Oncology (NASDAQ:KURA – Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%.The business had revenue of $20.87 million during the quarter, compared to the consensus estimate of $20.16 million. Analysts forecast that Kura Oncology, Inc. will post -3.25 EPS for the current year.

Wall Street Analysts Forecast Growth

KURA has been the subject of a number of recent research reports. Raymond James Financial set a $24.00 price objective on shares of Kura Oncology in a report on Monday, August 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kura Oncology in a research note on Friday, July 17th. Sanford C. Bernstein set a $24.00 price target on Kura Oncology in a research report on Monday, June 15th. Wedbush raised their price objective on Kura Oncology from $36.00 to $38.00 and gave the stock an “outperform” rating in a research note on Thursday, August 13th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a report on Thursday, June 4th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $25.40.

Read Our Latest Analysis on Kura Oncology

Trending Headlines about Kura Oncology

Here are the key news stories impacting Kura Oncology this week:

Positive Sentiment: KO-7246 regenerated functional pancreatic beta-cell mass and improved glycemic control in Type 1 and Type 2 diabetes models. Benefits persisted for at least one month after treatment stopped in a Type 1 diabetes model, suggesting potential disease-modifying activity. KO-7246 EASD announcement
Positive Sentiment: The candidate increased beta-cell mass, endogenous insulin and C-peptide levels, and showed enhanced activity when combined with semaglutide. Results in human pancreatic islets also indicated selective beta-cell proliferation and improved glucose-responsive insulin secretion, strengthening the potential commercial value of Kura’s menin-inhibitor platform. KO-7246 preclinical data
Neutral Sentiment: KO-7246 remains preclinical. Caspian plans IND-enabling work and a future Phase 1 study, with management scheduled to discuss the program on October 13. Any valuation benefit for KURA therefore depends on future clinical progress and the terms of Kura’s relationship with Caspian. Caspian and Kura KO-7246 report
Negative Sentiment: Several Kura executives and insiders sold shares on September 28–29, including Mollie Leoni, Brian Powl, Kathleen Ford, Thomas Doyle and Teresa Bair. The transactions totaled approximately 97,000 shares and more than $1 million, signaling near-term insider selling pressure even though the sellers retained substantial holdings. Kura insider ownership filing
Negative Sentiment: The diabetes opportunity carries substantial execution risk, including potential clinical or regulatory setbacks, unexpected safety findings and the need for additional financing before human trials can begin.

Institutional Trading of Kura Oncology

Several large investors have recently bought and sold shares of the business. IFP Advisors Inc grew its position in Kura Oncology by 115.3% in the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock valued at $25,000 after acquiring an additional 1,284 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Kura Oncology by 49.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 5,742 shares of the company’s stock worth $60,000 after acquiring an additional 1,888 shares during the last quarter. Pictet Asset Management Holding SA bought a new position in shares of Kura Oncology in the first quarter worth about $96,000. Allworth Financial LP acquired a new stake in shares of Kura Oncology in the 2nd quarter valued at approximately $113,000. Finally, E Fund Management Co. Ltd. acquired a new stake in shares of Kura Oncology in the 2nd quarter valued at approximately $132,000.

Kura Oncology Company Profile

(Get Free Report)

Kura Oncology, Inc is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research programs target specific genetic and molecular abnormalities that contribute to tumor growth, with an emphasis on hematologic malignancies and selected solid tumors.

Kura’s leading program has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia, including cancers with NPM1 mutations or certain KMT2A rearrangements.